For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

GLP-1 medications, like Ozempic and Wegovy, mimic natural hormones in the body that regulate blood sugar and insulin levels. They’re used to treat type 2 diabetes and obesity. These drugs curb the ...

There has been a lot of excitement since the launch. Not only is the drug extremely effective (people lose about 15 percent ...

Nearly three-quarters of U.S. adults are overweight or obese, according to a sweeping new study. The findings have ...

The weight-loss jab Wegovy made its debut on June 4 2021 . It was the first new weight-loss drug to be approved by the US ...

ReShape Lifesciences Inc. ( NASDAQ: RSLS) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO ...

Over the past three decades, there has been a startling increase in the prevalence of obesity across the U.S., at least ...

In a little over two decades, almost 260 million people in the United States are predicted to have overweight or obesity, ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Everyone is raving about the slimming power of semaglutide medications like Ozempic and Wegovy, which experts say is as ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.